BPI-9303A

BPI-9303A is an investigational antibody-drug conjugate (ADC) being developed by Beta Pharma for the treatment of solid tumors. As an ADC, it is designed to combine the targeting specificity of a monoclonal antibody with the potent cell-killing activity of a cytotoxic payload. The drug is intended to selectively bind to a specific antigen expressed on the surface of tumor cells, undergo internalization, and release its toxic payload to induce cell death while sparing healthy tissue. BPI-9303A is part of a broader suite of ADC candidates in Beta Pharma's oncology pipeline, which includes other early-stage assets such as BPI-9302A and BPI-9304A. The specific molecular target and payload mechanism for BPI-9303A have not yet been publicly disclosed.